Make circulating tumor DNA stand out among cell-free DNA



Turn insights into action
Guide adjuvant therapy
Early detection of recurrence
Therapy response
MRD testing can change the course of cancer care throughout the treatment journey2-5

Highly personalized, highly sensitive6
In the post-surgical setting, the Oncodetect MRD test correctly identified 78% of colorectal cancer patients whose cancer would recur.
In the surveillance setting, the Oncodetect MRD test correctly identified 94% of patients with stage III colorectal cancer whose cancer would not recur.
In the surveillance setting, the Oncodetect MRD test correctly identified 91% of patients with stage III colorectal cancer whose cancer would recur.
The tumor-informed Oncodetect MRD test analyzes up to 200 variants specific to your patient's cancer to detect even a slight amount of ctDNA.
The Oncodetect MRD test can detect cancer recurrence more than 2 years earlier than imaging.6
MRD testing could benefit over 3 million patients—including yours

Advancing MRD testing through cutting-edge technology and collaborative research

Ordering a test for your patients is fast and easy
Have questions?
References and footnotes
- Centers for Medicare & Medicaid Services, Medicare Coverage Database. LCD—MolDX: Minimal Residual Disease Testing for Cancer. Accessed January 21, 2025. https://www.cms.gov/
- Chakrabarti S, et al. Cancers. 2022;14:3078.
- Dasari A, et al. Nat Rev Clin Oncol. 2020;(17):757-770.
- Cohen SA, et al. Nature. 2023;619(7969):259-268.
- Malla M, et al. J Clin Oncol. 2022;40(24):2846-2857.
- Diergaarde B, Young G, Hall DW, Mazloom A, Costa G, Subramaniam S, Palomares M, Garces J, Baehner FL, Schoen RE; and other members of the Exact Sciences MRD Group. Circulating tumor DNA as a marker of recurrence risk in Stage III colorectal cancer: The α‐CORRECT study. Journal of Surgical Oncology.
- Santonja et al. EMBO. 2023. https://www.embopress.org/doi/full/10.15252/emmm.202216505
- Everett J. Moding, Barzin Y. Nabet, Ash A. Alizadeh, Maximilian Diehn; Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease. Cancer Discov 1 December 2021; 11 (12): 2968–2986
- Estimated turnaround times based on data on file from previous testing, actual turnaround times may vary.
- Internal validation data on file.
- Internal estimate for addressable patient populations based on solid tumors amenable to MRD testing.
-
The test has been validated in patients with stage II-IV colorectal cancer and Exact Sciences is currently pursuing applications in additional disease ontologies.
This test was developed, and its performance characteristics determined by Genomic Health, Inc. The Oncodetect test was clinically validated in colorectal cancer patients with stage II-IV disease. Performance characteristics may not apply in tumor types not included in this test’s clinical validation. The test has not been cleared or approved by the US Food and Drug Administration. The test has been validated as a Laboratory Developed Test per institutional and applicable CLIA regulation (CLIA# 03D2048606) and College of American Pathology (CAP# 8869063) as qualified to perform high complexity clinical laboratory testing.